Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases

被引：30

作者：

Ishikawa, Kiyohito ^{[1
,2
,3
]}

Hamasuna, Ryoichi ^{[1
,2
,4
]}

Uehara, Shinya ^{[1
,2
,5
]}

Yasuda, Mitsuru ^{[1
,2
,6
]}

Yamamoto, Shingo ^{[1
,2
,7
]}

Hayami, Hiroshi ^{[1
,2
,8
]}

Takahashi, Satoshi ^{[1
,2
,9
]}

Matsumoto, Tetsuro ^{[1
,2
,4
]}

Minamitani, Shinichi ^{[1
,2
]}

Kadota, Jun-ichi ^{[10
]}

Iwata, Satoshi ^{[10
]}

Kaku, Mitsuo ^{[10
]}

Watanabe, Akira ^{[10
]}

Sunakawa, Keisuke ^{[10
]}

Sato, Junko ^{[10
]}

Hanaki, Hideaki ^{[11
]}

Tsukamoto, Taiji ^{[9
]}

Kiyota, Hiroshi ^{[12
]}

Egawa, Shin ^{[13
]}

Deguchi, Takashi ^{[6
]}

Matsumoto, Minori ^{[14
]}

Tanaka, Kazushi ^{[14
]}

Arakawa, Soichi ^{[14
]}

Fujisawa, Masato ^{[14
]}

Kumon, Hiromi ^{[5
]}

Kobayashi, Kanao ^{[15
]}

Matsubara, Akio ^{[15
]}

Wakeda, Hironobu ^{[16
]}

Amemoto, Yoshinosuke ^{[17
]}

Onodera, Shoichi ^{[18
]}

Goto, Hirokazu ^{[18
]}

Komeda, Hisao ^{[19
]}

Yamashita, Masuo ^{[20
]}

Takenaka, Tadasu ^{[21
]}

Fujimoto, Yoshinori ^{[22
]}

Tsugawa, Masaya ^{[23
]}

Takahashi, Yoshito ^{[24
]}

Maeda, Hiroshi ^{[25
]}

Onishi, Hiroyuki ^{[26
]}

Ishitoya, Satoshi ^{[26
]}

Nishimura, Kazuo ^{[27
]}

Mitsumori, Kenji ^{[27
]}

Ito, Toru ^{[28
]}

Togo, Yoshikazu ^{[7
]}

Nakamura, Ichiro ^{[29
]}

Ito, Noriyuki ^{[30
]}

Kanamaru, Sojun ^{[30
]}

Hirose, Takaoki ^{[31
]}

Muranaka, Takashi ^{[31
]}

Yamada, Daisuke ^{[32
]}

机构：

[1] Japanese Assoc Infect Dis, Japanese Soc Chemotherapy, Urogenital Subcomm & Surveillance Comm, Tokyo, Japan

[2] Japanese Soc Clin Microbiol, Tokyo, Japan

[3] Fujita Hlth Univ, Sch Med, Dept Urol, Toyoake, Aichi 4701192, Japan

[4] Univ Occupat & Environm Hlth, Dept Urol, Fukuoka, Japan

[5] Okayama Univ, Dept Urol, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan

[6] Gifu Univ, Dept Urol, Grad Sch Med, Gifu, Japan

[7] Hyogo Coll Med, Dept Urol, Nishinomiya, Hyogo, Japan

[8] Kagoshima Univ Hosp, Blood Purificat Ctr, Kagoshima, Japan

[9] Sapporo Med Univ, Sch Med, Dept Urol, Sapporo, Hokkaido, Japan

[10] Surveillance Comm JSC JAID & JSCM, Tokyo, Japan

[11] Kitasato Univ, Kitasato Inst Life Sci, Res Ctr Antiinfect Drugs, Tokyo, Japan

[12] Jikei Univ, Dept Urol, Katsushika Med Ctr, Tokyo, Japan

[13] Jikei Univ, Sch Med, Dept Urol, Tokyo, Japan

[14] Kobe Univ, Grad Sch Med, Div Urol, Kobe, Hyogo, Japan

[15] Hiroshima Univ, Dept Urol, Inst Biomed & Hlth Sci, Hiroshima, Japan

[16] Miyazaki Univ, Fac Med, Dept Urol, Miyazaki, Japan

[17] Minami Med Hlth Cooperat, Dept Urol, Aichi, Japan

[18] Fuji City Gen Hosp, Dept Urol, Shizuoka, Japan

[19] Gifu Municipal Hosp, Dept Urol, Gifu, Japan

[20] Shinko Hosp, Dept Urol, Kobe, Hyogo, Japan

[21] Japanese Red Cross Okayama Hosp, Dept Urol, Okayama, Japan

[22] Ogaki Municipal Hosp, Dept Urol, Gifu, Japan

[23] Okayama City Hosp, Dept Urol, Okayama, Japan

[24] Gifu Prefectural Gen Med Ctr, Dept Urol, Gifu, Japan

[25] Yodogawa Christians Hosp, Dept Urol, Osaka, Japan

[26] Shiga Med Ctr Adults, Dept Urol, Shiga, Japan

[27] Osaka Red Cross Hosp, Dept Urol, Osaka, Japan

[28] Nagoya Ekisaikai Hosp, Dept Urol, Aichi, Japan

[29] Kobe City Med Ctr West Hosp, Dept Urol, Kobe, Hyogo, Japan

[30] Nishi Kobe Med Ctr, Dept Urol, Kobe, Hyogo, Japan

[31] Japan Community Hlth Care Org, Hokkaido Hosp, Dept Urol, Sapporo, Hokkaido, Japan

[32] Mitoyo Gen Hosp, Dept Urol, Kagawa, Japan

[33] Kizawa Mem Hosp, Dept Urol, Gifu, Japan

[34] Nara Social Insurance Hosp, Dept Urol, Nara, Japan

[35] Munakata Suikokai Gen Hosp, Dept Urol, Fukutsu, Japan

[36] Japanese Red Cross Kobe Hosp, Dept Urol, Kobe, Hyogo, Japan

[37] Natl Hosp Org, Iwakuni Clin Ctr, Dept Urol, Yamaguchi, Japan

[38] Hokkaido Social Work Assoc Obihiro Hosp, Dept Urol, Sapporo, Hokkaido, Japan

[39] Tottori Municipal Hosp, Dept Urol, Tottori, Japan

[40] Kagoshima Prefectural Ohshima Hosp, Dept Urol, Kagoshima, Japan

[41] Takikawa Municipal Hosp, Dept Urol, Sapporo, Hokkaido, Japan

[42] Fukuoka Shin Mizumaki Hosp, Dept Urol, Fukuoka, Japan

[43] Hiroshima City Asa Hosp, Dept Urol, Hiroshima, Japan

[44] Tenri Hosp, Dept Urol, Nara, Japan

[45] Kansai Elect Power Hosp, Dept Urol, Osaka, Japan

[46] Natl Hosp Org, Kure Med Ctr, Dept Urol, Kure, Japan

[47] Chugoku Canc Ctr, Kure, Japan

[48] Oji Gen Hosp, Dept Urol, Sapporo, Hokkaido, Japan

来源：

JOURNAL OF INFECTION AND CHEMOTHERAPY | 2015年 / 21卷 / 09期

关键词：

Surveillance; Susceptibility; Complicated urinary tract infection; MINIMUM INHIBITORY CONCENTRATION; STAPHYLOCOCCUS-AUREUS INFECTIONS; ACUTE UNCOMPLICATED CYSTITIS; ESCHERICHIA-COLI; RISK-FACTORS; RESISTANCE; PYELONEPHRITIS; ASSOCIATION; GUIDELINES; OUTCOMES;

D O I：

10.1016/j.jiac.2015.05.014

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

To investigate antimicrobial susceptibility patterns of various bacterial pathogens isolated from complicated urinary tract infection (UTI) cases, the Japanese Society of Chemotherapy, the Japanese Association of Infectious Disease, and the Japanese Society of Clinical Microbiology conducted the second nationwide surveillance from January to September 2011. With the cooperation of 42 medical institutions throughout Japan, 1036 strains belonging to 8 clinically relevant bacterial species were collected. Among methicillin-resistant Staphylococcus aureus (MRSA) strain, the vancomycin (VCM) MIC for 5.5% (3/55) of the strains was 2 mu g/mL. Ampicillin, VCM, and linezolid were relatively active against 209 Enterococcus faecalis strains. The proportion of fluoroquinolone (FQ)-resistant strains was >20%. The MIC90 of FQs against the 382 Escherichia coli strains was 2-64 mg/L and the proportion resistant to FQs was approximately 30%. However, susceptibility of E. coli to sitafloxacin was still high (MIC90 = 2 mg/L). Fifty-eight (15.2%) of 382 E. coli, 6 (4.5%) of 132 Klebsiella pneumoniae, 1 (2.4%) of 41 Klebsiella oxytoca and 4 (6.8%) of 59 Proteus mirabilis strains were suspected of producing extended-spectrum beta-lactamase. Of 93 Pseudomonas aeruginosa strains, the proportions resistant to imipenem, amikacin, and ciprofloxacin were 21.5%, 4.3%, and 20.4%, respectively. Four strains (4.3%) were found to be multidrug-resistant. In complicated UTI cases, all of MRSA and E. faecalis were susceptible to all anti-MRSA agents. Sitafloxacin was active against other FQ-resistant E. coli strains. The isolation of extended-spectrum betalactamase-producing and multidrug-resistant strains increased. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

引用

页码：623 / 633

页数：11

共 32 条

[1] Aeslen H, 2005, J ANTIMICROB CHEMOTH, V56, P914
[2] [Anonymous], INF DIS WEEKL REP JA
[3] [Anonymous], J MICROBIOL IMMUNOL
[4] [Anonymous], JPN J CHEMOTHER
[5] Use of administrative healthcare claims to examine the effectiveness of trimethoprim-sulfamethoxazole versus fluoroquinolones in the treatment of community-acquired acute pyelonephritis in women
Carrie, AG
Metge, CJ
Collins, DM
Harding, GKM
Zhanel, GG
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (03) : 512 - 517
[6] Clinical and Laboratory Standard Institute, 2012, M100S22 CLSI, V32
[7] Clinical and Laboratory Standards Institute, 2006, METH DIL ANT SUSC TE, V7
[8] Clinical and Laboratory Standards Institute, 2006, M45A CLSI
[9] Urinary Tract Infections Caused by Multi-Drug Resistant Proteus mirabilis: Risk Factors and Clinical Outcomes
Cohen-Nahum, K.
Saidel-Odes, L.
Riesenberg, K.
Schlaeffer, F.
Borer, A.
[J]. INFECTION, 2010, 38 (01) : 41 - 46
[10] Evaluation of a novel kit for the rapid detection of extended-spectrum beta-lactamases
Colodner, R
Reznik, B
Gal, V
Yamazaki, H
Hanaki, H
Kubo, R
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2006, 25 (01) : 49 - 51

← 1 2 3 4 →